New Uses of Lactic Acid Bacteria and Bifidobacteria
The invention comprises use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium and a mixture of any thereof in the manufacture of a food product, dietary supplement or medicament for lowering tissue inflammation (in particular, adipose, liver or muscle tissue inflammation) and treating cardiovascular disease in a mammal. The lactic acid bacteria and/or Bifidobacteria can also be used to treat diabetes and insulin resistance and induce enhanced secretion of insulin upon a glucose challenge and lower blood glucose levels without a concomitant decrease in weight gain.
1 - 69 . (canceled)
70 . A method of lowering tissue inflammation in a mammal, comprising administering to said mammal a bacterium of the species Lactobacillus acidophilus.
71 . A method according to claim 70 , wherein the tissue inflammation is adipose tissue inflammation.
72 . A method according to claim 70 , wherein the tissue inflammation is liver tissue inflammation.
73 . A method according to claim 70 , wherein the tissue inflammation is muscle tissue inflammation.
74 . A method of reducing the blood glucose level in a diabetic and/or obese mammal without a concomitant decrease in weight gain of said mammal, comprising administering to said mammal a bacterium of the species Lactobacillus acidophilus.
75 . A method of reducing insulin resistance in a diabetic and/or obese mammal without a concomitant decrease in weight gain of said mammal, comprising administering to said mammal a bacterium of the species Lactobacillus acidophilus.
76 . A method of treating diabetes in a mammal without a concomitant decrease in weight gain of said mammal, comprising administering to said mammal a bacterium of the species Lactobacillus acidophilus.
77 . A method of decreasing the metabolic consequences of diabetes in a diabetic and, optionally, obese mammal, comprising administering to said mammal a bacterium of the species Lactobacillus acidophilus.
78 . A method of improving glucose tolerance in a mammal, comprising administering to said mammal a bacterium of the species Lactobacillus acidophilus.
79 . A method of increasing fed insulin secretion in a mammal, comprising administering to said mammal a bacterium of the species Lactobacillus acidophilus.
80 . A method according to claim 70 , wherein the mammal is diabetic and obese.
81 . A method according to claim 70 , wherein the mammal is diabetic and non-obese.
82 . A method according to claim 70 , wherein the mammal is non-diabetic and obese.
83 . A method according to claim 70 , wherein the condition is diet-induced and/or diet-associated.
84 . A method according to claim 70 , wherein the mammal continues to gain weight during the course of the treatment.
85 . A method according to claim 70 , wherein the mammal continues to ingest a high-fat diet during the course of the treatment.
86 . A method according to claim 70 , wherein the bacterium is Lactobacillus acidophilus strain NCFM (ATCC PTA-4797).
87 . A method of treating cardiovascular disease in a mammal, comprising administering to said mammal a bacterium Lactobacillus acidophilus strain NCFM (ATCC PTA-4797).
88 . A method of treating metabolic syndrome in a mammal, comprising administering to said mammal a bacterium Lactobacillus acidophilus strain NCFM (ATCC PTA-4797).